See what’s new.
Duke Translational Chaperones help researchers secure over $6.5M in translational funding
In their pilot year, the new team at OTC worked with Duke life sciences PIs to position their research for maximal translational impact. Who will they help next?
Finding the right fit: inventive Duke students get crash course in commercializing their technologies
Making customer calls and polishing pitches – Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp.
Interdisciplinarity and impact shine at Duke Research and Innovation Summit 2025
The annual gathering of the Duke research community emphasized how innovators are making an impact through their research.
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
Duke, UNC, and NC State academics get crash course in building startups
Faculty and students with promising IP developed at Triangle universities were invited to workshop their ideas with the help of serial entrepreneurs.
Invented at Duke 2024 showcases the past and present of innovation at Duke, promising a bright future
A special Centennial edition of Invented at Duke featured inventors and innovations from the past, present, and future of Duke.
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
DANNCE.ai, a start-up from the lab of Assistant Professor Timothy Dunn (BME, Pratt), is also in the Duke Capital Partners portfolio.